Sp1248
STANDARD AND ALTERNATIVE THERAPIES FOR <i>H.PYLORI</i> INFECTION IN 2023
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
40 years after the organism was first recognized and grown in culture, Helicobacter pylori infections are still commonly encountered in practice,. This symposium will focus on several areas that remain unresolved to this day - including how best to manage H. pylori in children, the unappreciated side-effects of H. pylori therapy (including alterations in mucosal immunology and the microbiome that may have effects on other organ systems), and when and how to perform antibiotic resistance testing. The talks will conclude with an overview of the current and evolving best treatment options in 2023. LIVE STREAM SESSION
40 years after the organism was first recognized and grown in culture, Helicobacter pylori infections are still commonly encountered in practice,. This symposium will focus on several areas that remain unresolved to this day - including how best to manage H. pylori in children, the unappreciated side-effects of H. pylori therapy (including alterations in mucosal immunology and the microbiome that may have effects on other organ systems), and when and how to perform antibiotic resistance testing. The talks will conclude with an overview of the current and evolving best treatment options in 2023. LIVE STREAM SESSION
Presenter
University of California San Diego
Tracks
Related Products
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
INTRODUCTION
SOCIETY: AGA
